Outgoing Biogen CEO Michel Vounatsos told investors that the company believes new launches of biosimilars have the potential to drive renewed growth, particularly its “gradual” Byooviz (ranibizumab-nuna) launch, which is expected to make a more meaningful contribution to its revenue from 2023.
The biosimilars business, alongside wider near-term opportunities for Biogen, “have the potential to drive renewed growth and position us to have five key franchises by 2025